NEW YORK (GenomeWeb) – Cancer Genetics and Cellaria, a firm that develops cancer models, announced they are working together to develop precision medicine tools and platform technologies to support the development of oncology therapeutics.
Under the partnership, Cancer Genetics' Genomics Center of Excellence will characterize Cellaria's pipeline of commercial and custom-developed biopharma products, and employ its biomarker and genomics testing capabilities to improve understanding of patient diversity. The collaboration will focus on solid tumors in primary and metastatic disease.
The combination of Cellaria's in vitro expertise and Cancer Genetics' pharmacology expertise will create models that provide detailed and patient-specific assessments of response to therapy, the partners said in a statement.
"The addition of Cellaria as a channel partner and access to their in vitro capabilities will greatly enhance our preclinical and biopharma offerings," Cancer Genetics CEO John Roberts said in a statement. "We are also looking forward to utilizing our genomics and pharmacology services to develop novel, and informative, oncology models for Cellaria and Cellaria's biopharma clients that will accelerate their drug discovery and development efforts."